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I. INTRODUCTION 
1. COLORECTAL CANCER  
1.1 HISTORICAL PERSPECTIVE  
Believes and mysteries surrounding cancer have evolved throughout the history. An 
increased understanding of the disease has resulted in improved treatment. A brief 
review of some of the historical milestones of (colorectal) cancer is provided:  
Findings and examination of ancient mummies indicate that cancer occurred in 
prehistoric time. However, the first written description of cancer is found in the 
Edwin Smith Surgical Papyrus and the Ebers Papyrus 1. These papyri are based on 
what was known in surgery and medicine up to 3000 BC and 1500 BC, respectively. 
The Edwin Smith Surgical Papyrus contains the earliest description of breast cancer, 
with the conclusion that there is no treatment. In the Ebers Papyrus, enlarged 
thyroids; polyps; and tumours of the skin, pharynx, stomach, rectum, and uterus are 
described. Cancer was not a prevalent disease in antiquity, as most people did not live 
to see old age. 
People of prehistoric times believed that cancer was caused by evil spirits, 
natural forces, contact with wicked men, and disharmony of the planets. According to 
Hebrew, Greek, and Roman teachings, cancer was caused by sin, violation of 
religious rules, and the wrath of gods 1, 2.  
Hippocrates (BC 460-375), a Greek physician and the “father of medicine” in 
the Western tradition, was opposed to superstitions and hypothesized that tumours 
were caused by an imbalance of the four humours: blood, phlegm, yellow bile, and 
black bile. Hippocrates noted that growing tumours occurred mostly in adults and the 
growths reminded him of a moving crab, which led to the terms carcinos (a tumour), 
carcinoma (a malignant tumour), and cancer (a nonhealing malignant ulcer). The 
hard tumour, the scirrhus, was different from carcinos and carcinoma. The black bile 
was particularly bad. Hippocrates wrote of dark, beef glaze-like vaginal discharge in 
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association with enlargement and ulceration of the uterus. He recognized cancers of 
the skin, mouth, breast, and stomach. He knew about anorectal condylomas and 
polyps, and recommended examination with a speculum if they were higher up in the 
colon. Hippocrates summed up his recommendation for treatment by writing that 
tumours that are not cured by medicine are cured by “iron” (knife), those that are not 
cured by iron are cured by “fire” (cautery), and those that are not cured by fire are 
incurable. For occult or deep-seated tumours, he advised not to use any treatment 
because if treated, the patient would die quickly. If not treated, the patient could 
survive for an extended period. 
During the Roman Empire, the medical seat shifted from Greece to Rome. The 
Greek physician Claudius Galen (AD 131-203) believed that accumulation of black 
bile in the breast, uterus, lips, and in hemorrhoids caused cancer – a view that 
mirrored the humoral model of Hippocrates. Paracelsus postulated a similar view in 
the 16th century – that cancer was the cause of a fundamental mineral imbalance 
within the body (the mineral theory). The accumulation of noxious substances in 
blood as cause of cancer, led to the introduction of blood letting. However, Galen’s 
theory was accepted as a doctrine by medical practitioners and organized religions for 
sixteen centuries (2nd to 18th century), with little modification.  
The 18th century saw the first theories on the local origin of cancer. John 
Hunter proposed extravasated blood as a potential etiology 3. Use of the light 
microscope in the 19th century introduced the view of a cellular origin of cancer by 
investigators such as Rudolph Virchow and Karl von Rokitansky. During the 1920s, 
the theory of colorectal cancer arising from neoplastic polyps developed the early 
“adenoma-carcinoma-sequence” 4, 5. 
From the time of Hippocrates until the late 19th century, physicians and 
surgeons were convinced that surgical attempts at treating colorectal cancers were 
doomed to fail. This opinion stemmed from prevailing views on carcinogenesis 6. The 
three dominant theories, the humoral, mineral, and lymph theories, held that all 
cancers developed in tissue that had a diseased disposition. Thus, excision of the 
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gross tumour mass alone seemed unlikely to cure the patient. Consequently, surgical 
treatment of all cancers, and in particular colorectal cancer, was condemned.  
 
Figure: early anatomical drawing of the large bowel by Vesalius. 
The 19th century represented a transition period. Advances in surgical technique made 
excision of rectal cancers feasible. Unfortunately, classical views that resection of 
cancer was futile delayed the development of surgical treatment for colorectal cancer. 
Indeed, it was not until the late 19th century that a few individuals ignored these tenets 
of classical medicine and attempted local resections of rectal cancers. By the second 
quarter of the 20th century, a radical change occurred in the prevailing theories of 
carcinogenesis. Wide acceptance of the unicellular origin of cancer and the mucosal 
origin of colorectal cancers washed away admonitions against surgical treatment of 
colorectal cancers. It became axiomatic that all cancers, including colorectal cancers, 
could be cured surgically if treated while still a localized disease 3. 
The rigid proctoscope was initially described in 1853, but not practiced widely 
before after the 1900s. The remainder of the large bowel remained inaccessible until 
the development of the fiber-optic endoscopes in the 1960s. Colonoscopy, as a means 
of evaluating the entire colon was introduced in 1969 7, and by 1979 the Beth Israel 
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Medical Center in New York, USA had performed more than 7,000 endoscopic 
polypectomies 8. Although already introduced by Dukes in the 1920s, the polyp-
carcinoma-sequence was not widely adopted before the publications by Morson in the 
mid 1970s 9-11.  
Surgery for colorectal cancer was initially performed to relieve of intestinal 
obstruction, reportedly by creating stomas. Surgery for cure was made possible 
through the development of anti- and aseptic techniques in the latter part of the 19th 
century. Surgery of the intraperitoneal colon, which was more difficult to access, 
followed surgery of the sigmoid and rectum 3.  Throughout the latter part of the 20th 
century developments in surgical technique has improved patient survival, i.e. by the  
“no-touch” technique reported in the early 1950s and perfected by surgeons at the 
Cleveland Clinic12, and notably by the standards of total mesorectal excision (TME) 
for rectal cancers introduced by Heald in the early 1980s 13. The current focus is on 
the laparoscopic colectomy approach14, allegedly also giving the patient an 
immunologic advance by reduced surgical stress, which is believed to positively 
influence the (surgical) oncological outcome. 
 
1.2 EPIDEMIOLOGY 
Colorectal cancer (CRC) is the second most frequent cancer occurring in the Western 
world with about 1 million new cases developed annually 15. In Norway 16, about 
3,500 new patients develop CRC each year with a male:female ratio of about 1. The 
age-adjusted incidence has almost tripled over the past 50 years. Geographically, the 
risk of CRC varies (for unexplained reasons) from county to county in Norway, with 
the Rogaland County perceived as being a high-risk area with a high incidence of 
CRC. Very few cancers are diagnosed in the young (then, often associated with 
hereditary syndromes), and CRC is generally perceived as a disease of the old, with 
cumulative age-related incidence steadily increasing after the age of 50 years, with 
median age of those diagnosed being about 70 years. The number of cancers is 
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estimated to increase before reaching a plateau into the year 2020, except for an 
estimated continued increase in female rectal cancers. 
  
Figure: Cancer incidence 2001-2005 (top) and for year 2004 (bottom) with selected, 
frequently occurring cancers of solid organs, including digestive organs. Developed from 
www.kreftregisteret.no. 
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Figure: Colonic cancer. Developed from www.kreftregisteret.no. 
 
Figure: Rectal cancer. Developed from www.kreftregisteret.no. 
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1.3 RISK-FACTORS 
Colorectal cancer is a genetic disease, however, only 5-6% of cancers develop on a 
truly inherited genetic background 17. The most common, and best investigated, 
hereditary syndromes are the Familial Adenomatous Polyposis (FAP) syndrome 
caused by mutations in the APC gene, and the Hereditary Non-Polyposis Colorectal 
Cancer (HNPCC; the Lynch syndrome) caused by deficient DNA mismatch repair 
enzymes. Further, 10-20% of CRCs may have a ”familial” clustering of cases without 
any detectable or known specific genetic alterations leading to this increased risk; a 
relative risk of 2-3 is noted in those with a first-degree relative with CRC 18, 19. CRC 
may also develop on an inflammatory background, such as in long-standing 
ulcerative colitis, with cumulative probabilities for cancer development of 2% by 10 
years, 8% by 20 years, and 18% at 30 years 20.  
Nonetheless, the majority (70-80%) of CRCs are sporadic in nature, acquired 
through the accumulation of genetic “hits” over a lifetime. Truly, age is the single 
most important risk factor for developing CRC. Nonetheless, a long line of evidence 
indicates (as well as the geographical clustering with high incidences in the western 
world) that CRC is a lifestyle-related disease, with smoking, alcohol consumption, 
dietary factors, and physical inactivity all contributing to an increased risk 21-24. 
 
1.4 TREATMENT 
The only curative modality for CRC is surgery. New techniques give reduced surgical 
trauma, such as laparoscopic resection for CRC, while the indications for i.e. 
metastatic surgery is being widened, with improved results 14, 25. Adjuvant treatment 
(by different regimes) is given to patients operated on for cure who have lymph node 
metastasis (Dukes C, stage III cancers), while palliative chemo(-radio) therapy is 
given to those not amenable to curative surgery, or in an attempt to down-stage the 
tumour for resection. In particular, the neoadjuvant radiation approach for rectal 
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cancer continues to be discussed. Systemic treatment for CRC has improved over the 
last decades26, with a few “targeted therapies” already introduced, such as VEGF-
inhibitors 27-29. 
 
1.5 SURVIVAL 
Despite an overall increase in survival over the past 50 years, largely due to 
improvements in surgical technique and adjuvant therapy 30, still, 40-50% of those 
diagnosed with CRC are expected to die within 5 years of diagnosis due to recurrent 
disease. Survival is stage dependant, thus emphasizing the need for prevention and 
early detection and treatment of disease. Many prognostic factors have been introduce 
and investigated over time, while truly none have persisted to overtake the TNM-
system for prognostication. Some promising markers that have been investigated 
include microsatellite instability, thymidylate synthase expression, p53 expression 
and a number of other genetic abnormalities 31-36. While not perfect, the Dukes 
staging system guide prognostication and adjuvant treatment for most patients, with 
very good prognosis for Dukes A (>80-90% 5-year survival) and lowest survival for 
those with distant metastasis on diagnosis (Dukes D; <10-20% 5 year-survival). 
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1.6 SURVEILLANCE AFTER SURGERY FOR COLORECTAL CANCER 
Based on the notion that a large proportion of patients have recurrence despite 
surgery of curative intent, it has become common clinical practice to follow patients 
with CRC for several years following their definitive surgery and/or adjuvant therapy. 
Despite this widespread practice there is considerable controversy about how often 
patients should be seen, what tests should be performed, and whether these differing 
strategies have any significant impact on patient outcomes. In Norway, guidelines for 
surveillance after surgery in those <75 years of age have been made by the 
Norwegian Gastrointestinal Cancer Group (NGICG). The surveillance regimen is 
largely based on the diagnostic value of carcino-embryonic antigen (CEA) measured 
in the sera of patients 37. 
 
Figure: The Norwegian guidelines for follow-up after curative CRC surgery, developed from 
38, 39. 
 
North-American guidelines have focused on endoscopy in follow-up after curative 
resection for CRC 40, however, this modality received the lowest compliance in the 
evaluation in a defined Norwegian population 41. A recent (updated) Cochrane 
systematic review42, including eight randomized studies only, suggests that there is an 
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overall survival benefit for intensifying the follow up of patients after curative 
surgery for colorectal cancer. However, because of the wide variation in the follow-
up programs used in the included studies it was not possible to infer from the data the 
best combination and frequency of clinical visits, blood tests, endoscopic procedures 
and radiological investigations to maximize the outcomes for these patients. Nor was 
it possible to estimate the potential harms or costs of intensifying follow up for these 
patients in order to adopt a cost-effective approach in this area of clinical uncertainty. 
Thus, the surveillance after CRC resection remains an unresolved issue and a great 
socio-economic health burden, were best evidence suggest a positive effect of “doing 
something”, but just not what. Thus, it remains an unresolved issue what the optimal 
surveillance approach should be 42-45. 
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2. THE COLORECTAL POLYP  
A “polyp” is defined as any lesion of the colorectal mucosa protruding into the 
lumen. Polyps in the colorectum are (histologically) classified as either 
“hyperplastic” or “adenomatous”, with various variants in between. Hyperplastic 
polyps in the colorectum have traditionally been regarded as non-neoplastic, but K-
ras mutation is common, clonality has been demonstrated and biochemical 
abnormalities have been reported. Since the 1990s46, this topic has received 
tremendous attention, and it is now clear that the “serrated adenoma” in hyperplastic 
polyps represents a distinct pathway (epigenetically modulated) in current colorectal 
carcinogenesis understanding47-49. The polyps evaluated in this thesis contain but non-
herediatry, non-inflammatory, non-serrated colorectal adenomas diagnosed in 
symptomatic patients with no prior cancer history. 
 
2.1 COLORECTAL (PRE)NEOPLASIA 
The traditional understanding of developing CRC is based on the concept of the 
adenoma-carcinoma sequence. According to this theory, benign, (pre)neoplastic 
adenomas of the colorectal mucosa gradually transform to invasive cancer over time. 
Thus, the removal of adenomas has demonstrated a preventive effect on colorectal 
cancer incidence in several studies 50-55. However, controversial to this issue is the 
notion of the so-called (and disputed) “de novo” carcinogenesis, and the more recent 
developed principles of aberrant crypt foci described in the colorectum. 
The “de novo” carcinogenesis: According to some reports, between 20-
40% of all tumours may evolve from the colorectal mucosa de novo and grow 
invasively into the bowel wall 56-58. Adenomatous remnants in invasive cancer have 
been found only in about 20% of the tumours 58, 59. While the concept of de novo 
carcinogenesis was considered as a phenomenon related to Asian populations, it has 
gained more attention in the Western world during the past decade 60, 61 . 
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Aberrant Crypt Foci (ACF): The suggested first and earliest identifiable 
neoplastic lesions in the carcinogenetic model of the colon and rectum are so-called 
aberrant crypt foci (ACF) 62, 63. They are defined as small circumscript areas in the 
colorectal mucosa with enlarged crypts as compared to surrounding normal mucosa. 
It is thought that in the course of subsequent accumulation of biochemical and 
mutational changes some of the ACF develop to cancer. The progression of ACF to 
polyp and, subsequently, to cancer parallels the accumulation of several molecular 
alterations and mutations whereby a small fraction of ACF evolve to CRC. Recent 
data indicate that not uncommonly, some ACF bypass the polyp stage in their 
carcinogenesis thus reinforcing the importance of their early detection and the 
understanding of their pathogenesis. ACF show variable histological features 64, and 
can be grouped into differing categories by in vivo examination with high-
magnification-chromoscopic-colonoscopy (HMCC). As expected, ACF are more 
frequently detected in distal animal and human colons coinciding with the geographic 
distribution of CRC. Various markers may be altered within ACF suggesting possible 
prospective pathological changes. These transformations may lead to the 
identification of the earliest pathological features initiating colon cancerogenesis. The 
long line of evidence developed over the past decade suggest that ACF might be an 
important, yet unresolved, biomarker for CRC. While endoscopic techniques continue 
to evolve and thus changes the ways of early detection and diagnosis of 
(pre)neoplasia and early cancer, the colorectal polyp continues to be the main target 
lesion. 
 
2.2 CLASSIFICATION  
2.2.1 Macroscopy/endoscopy 
Colorectal neoplasia research has traditionally focused on exophytically growing 
(protruding) tumours. However, during the past decades, Japanese researchers have 
emphasized the importance of intramucosal premalignant and malign lesions with 
endophytical growth pattern and early invasion into the bowel wall. The first case of 
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depressed neoplastic lesions was reported by Kariya in 1977 65. Current concepts 
include both elevated, flat and depressed neoplastic lesions 66. As stated, high-
magnification-chromoscopic-colonoscopy (HMCC) and newer techniques (such as 
endoscopic DBI; double band imaging) will further alter the “macro-endoscopic” 
picture and retrieval of (pre-)cancers in the colon.  
 
2.2.2 Microscopy 
As such, definition of neoplasia in the colorectal mucosa remains a central issue. 
According to the WHO classification67, intramucosal neoplastic lesions are confined 
to the mucosal layer (i.e. mucosa, lamina propria and muscularis mucosae), and are: 
• graded to the degree of intraepithelial neoplasia (IEN) (low-grade vs. high-
grade), and  
• typed by their predominant histologic growth pattern as tubular, tubulovillous 
or villous.  
As depicted in this system, dysplasia is conventionally graded using a WHO two-tier 
system, with little/no room for “that what is in between”68. Low- and high-grade IEN 
convey different connotations regarding cancer risk. This perspective argues that the 
critical differential diagnosis is the one between neoplastic and non-neoplastic 
epithelial cell proliferations. The stepwise, continous model of (pre)cancer 
progression thus makes the relevance of IEN grading questionable. It is furthermore 
expected that a molecular signature will predict the propensity to invasive carcinoma 
more accurately than routine histopathology in the (near) future. Research in this field 
needs to focus on a combination of biomarkers representing the molecular spectrum 
of genomic and proteomic expressions. 
 Invasive cancer is defined as tumour invading beyond the muscularis mucosae 
layer into the submucosa. However, Japanese pathologists consider intramucosal 
lesions as early CRC based on other features than solely invasion like nuclear and 
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structural changes, thus possibly leading to higher incidence-figures of early 
malignant lesion in the colorectum 69. Accordingly, intramucosal lesions with high-
grade dysplasia as defined by WHO may be diagnosed as intramucosal cancer 
according to the Japanese criteria. However, there has recently been achieved an 
international consensus with regard to classification of gastrointestinal epithelial 
neoplasia (“Vienna classification”) 70. Further, a “malignant polyp” is one containing 
a cancer in situ, as defined by the Haggitt’s classification71. The latter lesions 
represent a synchronous (same time) occurrence of “cancer in adenoma”. On the 
other hand, a non-cancerous adenoma may predict a patient’s future risk of having 
new neoplasia/carcinoma develop (metachronous cancer). While several technical 
difficulties exist in the classification and accuracy of retrieved polyps/adenomas, 
ranging from the endoscopic procedures per se to the biopsy itself 72, 73, it is clear that 
improved tools for better classification is needed. 
 
2.2.3 Morphometry  
Generally, morphometrics (from the Greek "morph," meaning shape or form, and 
"metron”, meaning measurement) comprises methods of extracting measurements 
from shapes. Morphometry, as a part of quantitative pathology, has tried to classify 
tissue lesions in a metric (and preferably more objective) mode rather than the 
subjective assessment performed by pathologists. While morphometric measurements 
have been applied with a wide range of methods in colorectal neoplasia (from 
adenoma to carcinoma)74-80, there is considerably heterogeneity in the studies 
performed, and a general applicability and consensus for clinical practice has thus far 
not been reached. 
 
2.3 PREVALENCE 
The prevalence of colorectal adenomatous polyps varies widely from country to 
country 81-85. Among asymptomatic, average-risk patients, adenoma prevalence 
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averages approximately 10-20% in sigmoidoscopy studies and over 25% in 
colonoscopy studies, whereas the prevalence of colorectal cancer among these 
patients is less than 1% 81, 85. These data may change in the future due to the advent of 
new technological approaches and, in particular, chromo- and magnifying endoscopy 
as well as confocal laser endoscopy. The cumulative incidence of new adenomas 
within 3 years after normal endoscopy averages about 7% by flexible sigmoidoscopy 
and 27% by colonoscopy 82, 86. However, the true incidence rate is hard to estimate 
exactly, as it depends strongly on the definition used for diagnosis and selection 
criteria in the populations studied. Regional differences in adenoma prevalence rates 
demonstrates a clear, positive correlation with increasing age and with increasing 
incidence of cancer in the population under study; with 4-6% of those under 50 years 
having adenomas, and up to 50-60% of those >75 years having an adenomas 81, 83.  
 
2.4 DETECTION AND PREVENTION 
As adenomas are believed to be the precursor to colorectal cancer, its detection and 
removal, or frank prevention from developing in the first place, is though of as the 
cornerstone in reducing the in incidence and, consequently, mortality from CRC. In 
this aspect, there is a plethora of approaches to achieve this; ranging from 
chemopreventive strategies87, 88, to occult fecal blood or molecular detection 
mechanisms89-91, “virtual colonoscopy” by modern multi-slice computer 
tomography92, and various screening programs using endoscopic techniques 51, 85, 93. 
While detection and removal of adenomas are feasible by endoscopic techniques, the 
majority of adenomas are thought to never develop into cancer. In fact, evidence 
suggest that a number of adenomas regress over time when left in situ. Thus, defining 
the “high risk” adenoma, and consequently defining the patients, requiring closer 
surveillance is a major research target. As such, the adenoma is a “surrogate endpoint 
biomarker”94, 95, however, defining characteristics within the adenoma (-patient) 
would further narrow the target group for enhanced surveillance.  
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2.5 SURVEILLANCE AFTER POLYPECTOMY 
Consequently, defining high-risk adenomas is important for surveillance strategy, 
follow-up intervals and intervention planning according to individual risk 96. 
Evidence suggests that multiplicity (≥3 adenomas), size (≥1 cm), villous features, and 
high-grade dysplasia are predictors of future advanced adenomas or cancers 97, 98. 
However, the studies from which these data derive are heterogeneous. The distinction 
between synchronous and metachronous CRC have not always been made, and 
studies have found an intriguing high rate of cancer in the early period of surveillance 
99, 100, indicating a high likelihood for “missed” advanced adenomas or (pre)cancers at 
index colonoscopy. Yet, still, the adenoma size, numbers, and histologic grade are the 
features by which current surveillance is guided. While adenoma numbers can be 
counted and size can be measured, the histologic type and grade has to be judged – an 
art well, but not perfectly, performed by pathologists 101. Few published studies 
stratify the incidence of advanced adenomas at surveillance colonoscopy according to 
index colonoscopy findings. In the future, large prospective studies or studies using 
pooled data from existing randomized controlled trial databases or polyp registries 
should be used to better define which patients are at low vs high risk for advanced 
adenoma recurrence. Thus, future screening and surveillance strategies should 
preferably be tailored after other and better surrogate endpoint biomarkers within the 
colorectal mucosa than the traditional adenoma features. 
 25 
3. COLORECTAL CARCINOGENESIS 
3.1 THE HALLMARKS OF CANCER 
Cancer is now understood as the result of an accumulation of genetic alterations that 
allows growth of neoplastic cells with certain phenotypic hallmark characteristics102. 
Each tumourtype may show tissue- (and even patient)-specific molecular alterations 
that, however, as an endpoint goal of every neoplastic cell, serve to provide the 
cancer cell for:  
• self-sufficiency in growth signals (i.e through mutated oncogenes),  
• insensitivity to anti-growth signals (i.e. mutated tumour suppressor genes),  
• evasion of apoptosis (loss or inhibition of apoptosis signals),  
• limitless replicative potential (gain of telomerase function),  
• sustained angiogenesis (increased vascularity for nutrition),  
• the ability to invade tissues and metastasize (“seed & soil” capacity in tissues)103.  
 
Figure: The hallmarks of cancer. 
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This can be achieved through various molecular mechanisms, complicating the 
network and understanding of carcinogenesis. Cancer development follows a clonal 
evolution with continuous accumulation of mutations contributing to the acquirement 
of the required phenotypic cancer hallmarks. In essence, a tumour forms from any 
single aberrant cell, which may, through further cell division, develop into an 
accumulation of preneoplastic cells (i.e. polypous growth), again forming into a 
precursor lesion (i.e. adenoma), further acquiring malignant features (i.e. carcinoma) 
and then invade and spread to distant sites (metastasis, such as in liver or lungs). 
 
3.2 COLORECTAL CANCER DEVELOPMENT 
Development of CRC from an adenoma to carcinoma may take several decades. In 
the colorectum, a continuous turnover of the epithelium occurs, with a shift of the 
epithelial lining every 4-6 days. Thus, the continuous exposure to various intestinal, 
luminal contents, and the potential for acquiring early mutative events in cryptal stem 
cells, may in due time cause neoplastic transformation and cancerous overgrowth in 
the large bowel 104. Stem cells share many properties with malignant cells, such as the 
ability to self-renew and proliferate. Colorectal cancer (together with many other 
cancers) is believed to be a disease of stem cells105. The gastrointestinal tract has high 
cancer prevalence partly because of rapid epithelial cell turnover and exposure to 
dietary toxins. The molecular pathways of carcinogenesis differ according to the 
tissue involved (e.g., pancreas, biliary tree, colorectum)17, 106, 107, although similarities 
exist.  
Research on hereditary cancer syndromes, including familial adenomatous 
polyposis (FAP), has led to advances in the understanding of the events that occur in 
tumour development from a gastrointestinal stem cell. The initial mutation involved 
in the adenoma-carcinoma sequence is in the “gatekeeper” tumour-suppressor gene 
adenomatous polyposis coli (APC). Somatic hits in this gene are non-random in FAP, 
with the type of mutation selected for by the position of the germline mutation. 
Clonal expansion of mutated cells occurs by niche succession. Further, expansion of 
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the aberrant clone then occurs by the longitudinal division of crypts into two daughter 
units, called crypt fission104, 108, 109. 
 
Figure: Crypt development in the intestine. From Radtke & Clevers. Self-renewal and cancer 
of the gut: two sides of a coin. Science 2005; 307: 1904-9 104. Reprinted with permission from 
AAAS. 
Two theories seek to explain the early development of adenomas: the “top 
down” and “bottom up” hypotheses109, 110. Initial studies suggested that colorectal 
tumours were monoclonal; however, later work has suggested that up to ¾ of early 
adenomas are polyclonal. Introduction of a homozygous resistance allele has reduced 
tumour multiplicity in the mouse and has been used to rule out random collision of 
polyps as the cause of these observations. It is likely that short-range interaction 
between adjacent initiated crypts is responsible for polyclonality105. Also, evolving 
data suggest that cancer polyclonality is caused by epigenetic disruption of 
stem/progenitor cells. Thus, cancer heterogeneity may be due in part to epigenetic 
variation in these progenitor cells, and epigenetic plasticity together with genetic 
lesions drives tumour progression. This crucial early role for epigenetic alterations in 
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cancer, is in addition to epigenetic alterations that can substitute for genetic variation 
later in tumour progression. Therefore, non-neoplastic but epigenetically disrupted 
stem/progenitor cells might be a crucial target for cancer risk assessment and 
chemoprevention in the future111. 
Invasion by colorectal carcinomas is characterized by an epithelial-
mesenchymal transition (EMT)-like dedifferentiation of the tumour cells involving 
several mechanisms112. However, a redifferentiation towards an epithelial phenotype, 
resembling a mesenchymal-epithelial transition, is detectable in metastases. This 
indicates that malignant progression is based on dynamic processes, which cannot be 
explained solely by irreversible genetic alterations, but must be additionally regulated 
by the tumour environment. In fact, there is a growing attention to the extracellular 
matrix which surrounds the tumour tissue, where inflammatory mechanisms and 
protease-systems among others are believed to foster invasiveness and metastasis in 
the epithelial tumour cells113-115. At the same time, several factors in the extracellular 
matrix may in fact prevent cancer progression, invasion and metastasis103, 116. Thus, 
the complexities herein will continue to receive much attention in the years to come.  
 
Figure. General depiction of the extracellular matrix (ECM) and factors involved in cancer 
development, progression and metastasis. Developed from Søreide et al 114.  
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The multigene, clonal evolution, and selection model of initiation and progression of 
CRC proposed by Fearon & Vogelstein originally identified the APC gene, genes on 
18q, and the K-ras and p53 genes as those in which mutations contribute to the 
evolution of CRC 117. Although confirmed by later studies, many additional genes are 
also involved. In fact, the recent understanding of the heterogeneity in colorectal 
carcinogenesis involves mechanisms related to chromosomes, to microsatellites, or to 
epigenetic phenomena, all distinctively driving the cells into cancer via several 
possible pathways of proliferation, invasion and metastasis 17, 47, 48, 114, 118-124. 
Consequently, rather than representing a linear model of required accumulative 
mutations in the APC, K-ras, and p53 genes (< 10% of all CRCs have all mutations) 
recent studies suggest they may each represent alternative, multiple mutational 
pathways in colorectal cancerogenesis 125, with specific associated chromosomal 
aberrations126, and distinct clinical outcomes 123. 
Knowledge derived from families with Familial Adenomatous Polyposis 
(FAP) or Hereditary Non-Polyposis Colorectal Cancer (HNPCC) helped establish the 
early model of colorectal carcinogenesis 117, 127. Hereditary syndromes have germline 
mutations in specific genes (such as mutation in the tumour suppressor gene APC on 
chromosome 5q in FAP; mutated DNA-mismatch repair genes in HNPCC) that 
greatly increase the lifetime risk for developing CRC (>80% in HNPCC) compared to 
the general population.  
Sporadic CRC develops through randomly acquired somatic mutations in 
several of the same genes found in hereditary cancers 17. However, the rate of random 
mutational events alone cannot account for the number of genetic alterations found in 
most human cancers 128. For this reason, it has been suggested that destabilization of 
the genome may be a prerequisite early in carcinogenesis 129. This "mutator 
phenotype" is best understood in CRC, in which there are (at least) two separate 
destabilizing pathways – chromosomal and microsatellite instability. 
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Figure: The adenoma-carcinoma sequence (Vogelstein model) incorporating the CIN and 
MSI pathway, the latter including the epigenetic pathway (adopted from Søreide et al17  
with permission. Copyright  British Journal of Surgery Society Ltd. Reproduced with 
permission. Permission is granted by John Wiley & Sons Ltd on behalf of the BJSS Ltd. 
 
3.3 GENETIC INSTABILITY & CANCER 
 Most cancers arise through clonal selection and waves of expansion of a somatic cell 
that has acquired genetic alterations in essential genes either controlling cell death or 
cell proliferation. Furthermore, stability of the genome in cancer cells becomes 
compromised because several cancer-predisposing mutations affect genes that are 
responsible for maintaining the integrity and number of chromosomes during cell 
division. Genetic instability may involve several genes at different levels; however, 
three major, independent or overlapping levels of instability seem to be crucial in 
carcinogenesis.  
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Figure: The double helix – DNA depicted from chromosomes to basepairs. Reprinted by 
permission from Macmillan Publishers Ltd: Nature130, copyright 2003. 
 
3.3.1 Chromosomal instability (CIN) 
Chromosomal instability (CIN) is a defining characteristic of most human cancers131, 
132. Mutation of CIN genes increases the probability that whole chromosomes or large 
fractions of chromosomes are gained or lost during cell division. The consequence of 
CIN is an imbalance in the number of chromosomes per cell (aneuploidy) and an 
enhanced rate of loss of heterozygosity (LOH). A major question of cancer genetics is 
to what extent CIN, or any genetic instability, is an early event and consequently a 
driving force for tumour progression.  
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The archetypical transformation in cancer cells, including CRC, results in 
aneuploidy. Indeed, almost all cancer cells display a host of karyotype alterations, 
showing translocations, gains or losses of entire or large parts of chromosomes. 
Cancers do not necessarily have a higher mutation rate than normal tissue at the 
nucleotide level, unless they have gained a mutator phenotype through exposure to 
environmental stress, but rather exhibit gross chromosomal changes. Therefore, it 
appears that the main mechanism of tumour progression stems from chromosome 
instability. Chromosomal instability prevailing in cancer cells arises through several 
different pathways and is probably controlled by hundreds of genes. The main factors 
that control chromosome stability are telomere maintenance133, 134, mechanisms of 
cell division, and the mitotic checkpoints that govern centrosome duplication and 
correct chromosome segregation131, 135-137. 
The most common genetic pathway (approximately 85% of CRCs) is 
characterized by allelic losses, chromosomal amplifications, and translocations 48, 127, 
138-146. Deletion at 1p and 8p, as well as loss of heterozygosity (LOH) of 17p and 18q 
are frequent in CRC. Such alterations are characteristic of the chromosomal-
instability pathway (CIN), also referred to as the microsatellite-stability pathway 
(MSS). Various techniques exist for investigating abnormalities at the chromosome 
level, including conventional karyotyping, fluorescence in sity hybridization (FISH), 
flow cytometry (ploidy analysis), comparative genomic hybridization (CGH) and 
spectral karyotyping (SKY), and are described more detailed elsewhere 147, 148. 
 
3.3.2 Microsatellite instability (MSI) 
The second pathway (involving about 15-20% of sporadic CRCs) is referred to as the 
microsatellite-instability pathway (MSI) 17. Such tumours display base-pair 
substitutions that are commonly found in short, tandemly repeated nucleotide 
sequences known (i.e. CACACACA; or [CA]4) as “microsatellites” 149-153. This form 
of genetic destabilization is most commonly caused by loss of the DNA mismatch-
repair function. The consequence is repeatedly inbuilt errors in microsatellite 
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sequences, often causing frameshift mutations and protein alterations in the 
microsatellite instable sequences, and thus leading to carcinogenesis.  
Microsatellites are found in great number spread out over the whole DNA 
sequence and, due to their repetitive manner, are prone to changes during replication. 
The most common microsatellite in humans is a dinucleotide repeat of cytosine and 
adenine which occurs in several thousand locations throughout the human germ 
line153.  Mismatches of nucleotides occur when the DNA-polymerase inserts the 
wrong bases in the newly synthesized DNA. Normally, when two strands of DNA 
replicate, nucleotide mismatches occur, but almost all such errors are quickly 
corrected by a molecular proofreading mechanism. The DNA mismatch repair system 
works as a “spell checker” that identifies and then corrects the mismatched basepairs 
in the DNA. However, defects in the mismatch repair mechanisms (i.e. mutated 
genes) lead to MSI.  
Microsatellite instability was discovered to be a marker in HNPCC more than 
a decade ago153, 154, when searching for loss of heterozygosity (LOH) in the 
susceptible region to find a tumour suppressor gene among dinucleotide repeats. 
Instead, microsatellites that had changed in length were found in all the HNPCCs – 
not only in the critical genetic region, but virtually everywhere in the genome of the 
tumour. This phenomenon was termed "replication error" (RER) and later renamed 
"microsatellite instability”153-156. Widespread MSI in HNPCC is associated with 
defective DNA-mismatch repair proteins caused by germline mutation of one of the 
three main genes (MLH1, MSH2, and MSH6). As a consequence, the lifetime risk for 
developing CRC is >80% for HNPCC offspring, compared to a lifetime risk for CRC 
of up to 5-6% in the general population157, 158. In addition, the risk is greatly elevated 
for endometrial cancer (lifetime risk of 50-60%, compared to 2-3% in the general 
population), moderately increased in ovarian and gastric cancer (12% and 13%, 
respectively)157, 159, but equals the normal population for lung, prostate, or breast 
cancer. Deficient mismatch repair occurs in approximately 15% of all sporadic CRC. 
In contrast to HNPCC, the cause in sporadic CRC is methylation of cytosine residues 
of the cytosine and guanine (CpG)-rich promoter sequences of MLH1160-163. Simply 
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stated, the ‘epigenetic change’ affect gene function (without genetic changes) by 
aberrant methylation of DNA that prevents the gene (-region) from being transcribed, 
thus ‘silences’ the gene, and cause deficiency in protein expression (see section on 
“epigenetics”).  
  
Testing for MSI 
The choice of microsatellite markers is important for MSI testing164. Testing for MSI 
can be done at the protein level with immunohistochemistry, but genotyping by 
means of the polymerase-chain-reaction (PCR) is the “gold standard”. Mutations that 
alter microsatellite length (by deletion or insertion) are visualized as bandshifts on 
either electrophoresis, or by sequencing. The latter is the preferred method. 
 Immunohistochemistry (IHC), although proposed to be more cost-effective than 
PCR, is currently not sensitive and specific enough to be used routinely in detecting 
MSI in sporadic and hereditary CRC. The reasons for this are several; the 
heterogeneity within tumours; the weak and focal IHC staining patterns that may be 
associated with MSI or gene mutation, or both; variability in technical protocols for 
fixation and staining quality within laboratories; and differences in interpretation of 
results. The rate of normal IHC results (but with PCR detected mutations) ranges 
from 2 to 36% in the literature165-167, and PCR has a higher sensitivity and specificity 
compared to IHC168. One of the major problems with IHC is detection of the 
frequently altered MLH1 gene mutations (sensitivity <50%). 
The 1997 Bethesda Guidelines169, 170 proposed a panel of five microsatellite 
markers for the uniform PCR analysis of MSI in HNPCC. This panel included two 
mononucleotide (BAT-25 and BAT-26) and three dinucleotide (D5S346, D2S123, 
and D17S250) repeats. The Bethesda guidelines have since been revised171, as the use 
of dinucleotide repeats may cause under- and overestimation of the instability-status. 
The revision mainly recommends the use of more mononucleotide markers in 
unequivocal cases (i.e. in only dinucleotide unstable cases). 
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Screening for HNPCC using the recommended Bethesda MSI markers are now 
performed in trials for detection of HNPCC172, 173, however, the current diagnostic 
yield and implemented costs demand for cautious expectation at best174. Although 
feasible, the choice to screen all patients who have CRC for MSI should await further 
evidence relating to the clinical importance and therapeutic influence of this 
information. Clearly, the many available techniques and numbers of markers for MSI 
testing make general comparison of the obtained clinical outcomes difficult in both 
hereditary and sporadic CRC175, 176. However, knowledge is evolving rapidly in this 
field of CRC research. 
 
Microsatellite frequency 
For whatever the number of microsatellite markers that are used in a panel, instability 
in ≥ 40% of markers (i.e. 2 of 5 markers in the Bethesda panel) is defined as high-
frequency MSI (MSI-H), while instability in 20-40% of markers are defined as low-
frequency MSI (MSI-L). Tumours with no proven instability (or ≤20%) are termed 
microsatellite stable (MSS) – these tumours comprise those said to follow the CIN-
pathway. The existence of MSI-L is still controversial and under debate177-181. 
Complexities are related to the wide genomic distribution of dinucleotides, the yet 
unresolved molecular alterations that have been found in these markers, and the 
possible influence on carcinogenesis178, 181-183. When many dinucleotide markers are 
used, a large number of CRC are graded as MSI-L181. The select use of 
mononucleotide markers may avoid this problem177, 184, 185. However, proponents of 
MSI-L tumours have found frequent k-ras mutations, as well as more frequently LOH 
at 5q, 1p and 8p140, relating them to the CIN-pathway180 while this has not been 
confirmed in other studies181. Interestingly, some MSI-L tumours are epigenetically 
silenced in the DNA-repair gene MGMT (O-6-methylguanine DNA 
methyltransferase) more frequently than both MSI-H and MSS cancers186, which may 
pose a different way to DNA repair errors.  MSI-L status has been related to poor 
prognosis in patients with stage C cancers187. Although techniques to more readily 
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detect these subtle differences are developing, such as hypermethylation of MGMT188, 
the true clinicopathological yield of MSI-L status remains to be established. 
 
Genetic differences 
Tumours exhibiting CIN and MSI resemble each other in all but a few distinct ways. 
Tumours with CIN have mutations in p53 and APC, including gross chromosomal 
abnormalities. In contrast, tumours with MSI have frameshift mutations in specific 
target genes, such as β-catenin and TGFβRII189, and fewer mutations are found in k-
ras and p53190. The same holds true for allelic imbalance at other genetic loci, such as 
18q. Mutations of p53 are associated with poor prognosis35, explaining in one way the 
prognostic advantage of MSI tumours. However, MSI-positive tumours that express 
p53 seem to have a more aggressive biology than their p53-negative counterparts191. 
 Defective mismatch repair presumably facilitates malignant transformation by 
allowing the rapid accumulation of mutations that inactivate genes, which ordinarily 
have key functions in the cell. The lack of mismatch-repair proteins, fails to correct 
nucleotide mismatches and thus promotes mutations in other genes. However, genes 
carrying MSI in their own coding sequences are also involved, such as the BAX and 
TGFβRII genes192.  
 A frameshift mutation inactivates the BAX gene in about 35% of all tumours 
with MSI. Altered BAX-expression is believed to contribute to carcinogenesis by 
disrupting the apoptosis pathway mediated by Bcl-2 193-198.  
 The TGFβRII gene, which encodes transforming growth factor β (TGF-β) 
receptor II199, undergoes a frameshift in up to 90% of all HNPCC. This mutation 
leads to a disruption in the function of TGF-β, which acts as both a tumour 
suppressor and promoter in CRC200-204. TGF-β signalling pathway involves activation 
of the Smad proteins which regulate transcription. Other genes with coding 
microsatellites (i.e. the tumour-suppressor gene p16INK4A) are mutated in mismatch-
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repair–deficient CRC, but their precise roles are not well understood. More recently, 
the use of array technology has identified a number of genes differentially expressed 
in the two subtypes of CRC205-208. 
 
Clinicopathological implications 
Distinct clinical and pathological features of CRCs arising from the two separate 
mutational pathways have been identified191, 209-211.  
 
Figure: Clinicopathological characteristics of MSI vs CIN tumours of the large bowel. 
Adopted from Søreide et al17. Copyright  British Journal of Surgery Society Ltd. Reproduced 
with permission granted by John Wiley & Sons Ltd on behalf of the BJSS Ltd. 
 
MSI is observed more frequently in women and in CRCs that occur proximal to the 
splenic flexure. These tumours also exhibit poor differentiation, a mucinous cell type, 
and frequently peritumoural lymphocytic infiltration (“Crohns-like inflammation”)209, 
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212, 213. By which mechanisms this inflammatory response may contribute to the better 
prognosis remains to be fully explained, but the cytotoxic effects of CD8+ 
lymphocytes seem to be important212, 213. Recent data suggests an interplay with TGF-
β and peritumoural lymphocytes200.  
Furthermore, MSI tumours are usually diploid unlike the often aneuploid CIN 
tumours. CRC exhibiting MSI is associated with a larger size (i.e. T3 tumours) of the 
primary tumour, but with a more favourable stage distribution (less lymph node 
involvement and reduced occurrence of metastasis). The pronounced genetic 
instability of cells with MSI may increase susceptibility to apoptosis because of an 
accumulation of mutations in genes that are required for cell growth. An increased 
rate of mutation in other genes might lead to aberrantly expressed proteins in 
membranes, which may be associated with the antitumour immune response 
evidenced by the lymphocytic infiltrates that surround tumours with MSI209, 212, 213. 
MSI cancers have a higher incidence of synchronous and metachronous 
tumours. In a recent study Velayos et al214 explored the MSI patterns in patients with 
metachronous and synchronous CRC. They found that MSI occurred with equal 
frequency among patients with synchronous and metachronous CRCs. However, the 
underlying mechanism for MSI was different (loss of MLH1 expression associated 
with promoter hypermethylation was more common in MSI-H synchronous CRC). 
Observed differences in MLH1 promoter hypermethylation and patient characteristics 
suggested that most MSI-H synchronous CRCs were sporadic in origin214. 
Most importantly, patients with CRCs that exhibit MSI have longer overall 
and cancer-specific survival than stage-matched patients with cancers exhibiting 
CIN33, 215. The important contrast in survival between the two types of CRC remains 
unexplained. Paradoxically, colorectal cancers with MSI bear many features that are 
generally associated with poor prognosis, including deep tumour invasion and low 
histologic differentiation. However, MSI positive tumours are rarely found in hepatic 
metastasis from CRC216.  
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Adjuvant chemotherapy with fluorouracil benefit patients with tumours 
exhibiting CIN, but apparently not those with tumours exhibiting MSI217. However, 
an overall reduced benefit from adjuvant therapy in patients with MSI and CRC could 
not be demonstrated in a recent systematic review and metaanalysis33, but the overall 
survival of MSI colorectal tumours was better. Thus, the mechanism in which MSI 
tends to render clinically less aggressive cancers remains an interesting but 
unresolved research target. Real differences in adjuvant chemotherapy response 
between MSI and CIN tumours remain to be demonstrated. 
 
3.3.3 Epigenetic silencing 
Aberrations in the DNA methylation patterns are recognized as a hallmark of human 
cancer development, and so-called “epigenetic silencing” is now recognized as a 
'third pathway' in Knudson's model of tumour-suppressor gene inactivation in 
cancer208, 218, 219. One of the most characteristic changes is the hypermethylation of 
CpG islands of tumour suppressor genes associated with their transcriptional 
silencing.  
CpG islands are regions where there are a large number of cytosine and 
guanine adjacent to each other in the backbone of the DNA (linked by phosphodiester 
bonds; thus named CpG). They are in and near approximately 40% of promoters of 
mammalian genes (about 70% in human promoters). The length of a CpG island is 
typically 300-3000 base pairs. These regions are characterized by CpG dinucleotide 
content equal to or greater than what would be statistically expected (approx. 6%), 
whereas the rest of the genome has much lower CpG frequency (approx. 1%), a 
phenomenon called CG suppression. Unlike CpG sites in the coding region of a gene, 
in most instances, the CpG sites in the CpG islands of promoters are unmethylated if 
genes are expressed. This observation led to the speculation that methylation of CpG 
sites in the promoter of a gene may inhibit the expression of a gene. Methylation is 
central to imprinting along side histone modifications. The usual formal definition of 
a CpG island is a region with at least 200 bp and with a GC percentage that is greater 
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than 50% and with an observed/expected CpG ratio that is greater than 0.6. Most of 
the CpG islands are associated with genes, and can be used as recognition sites for 
restriction enzymes. 
The target genes of epigenetic silencing are distributed in all cellular pathways 
(e.g. apoptosis, DNA repair, cell cycle, cell adherence), and are thought of as early 
initiators of carcinogenesis220, 221. They are "classical" tumour suppressor genes with 
associated familial cancers (e.g. BRCA1, hMLH1, p16INK4a, VHL) and putative new 
tumour suppressor genes which loss may contribute to the transformed phenotype 
(e.g. MGMT, p14ARF, GSTP1, RARB2). A tumour-type specific profile of CpG 
island hypermethylation exist in human cancer that allows the use of these aberrantly 
hypermethylated loci as biomarkers of the malignant disease. The eruption of new 
technologies for the careful study of the DNA methylation patterns, and their genetic 
partners in accomplishing gene silencing, may also provide us with new drugs for the 
epigenetic treatment of human tumours. 
For selected genes, epigenetic changes are tightly related to neoplastic 
transformation in CRC. As an example, loss of the tumour suppressor gene PTEN 
located at 10q23 occurs through promotor hypermethylation in CRC with MSI-H206. 
In the colon, aberrant DNA methylation arises very early, initially in normal mucosa, 
and may be part of the age-related field defect observed in sporadic CRC. Aberrant 
methylation also contributes to later stages of CRC formation and progression 
through a hypermethylator phenotype termed CpG Island Methylator Phenotype 
(CIMP). CIMP appears to be a defining event in about half of all sporadic CRCs222. 
CIMP-positive CRCs are distinctly characterized by pathological, clinical and 
molecular genetic features222-225. 
 MSI in sporadic CRC usually arises because of epigenetic silencing of the 
DNA mismatch repair gene MLH1226, and is thus associated with methylation, but the 
overlap of “mutator” and “methylator” phenotypes is not exact149, 152, 227. In particular, 
some cancers with extensive DNA methylation do not show the mutator phenotype. 
Although DNA methylation is associated with a worse outcome in CRC, this adverse 
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prognostic influence is lost in methylated tumours with MSI228. Collectively, these 
factors add a layer of complexity to the clinical, morphological, and molecular 
classification of CRC47. 
 
3.4 PROLIFERATION AND APOPTOSIS 
The balance between “life and death” is essential in all tissue development, and also 
in development of neoplasia and cancer. Colorectal cancer has served as a model for 
the detection and description of several important genes and the molecular pathways 
they control 229. Basically these genes regulate the inner cellular network, leading to 
the endresult of either cell proliferation or apoptosis. However, cross-talk among 
several pathways exists, and the true function of certain proteins/factors may differ 
with “time and dose” of their presence204. A brief outline of a few pathways are given 
here. 
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Figure: Several molecular pathways are involved in colorectal cancer development, of 
which a simple outline is given here. Developed from Søreide et al 17.  
 
3.4.1 Proliferation 
WNT-pathway: The “WNT”, or “wingless” (so named for the mutator effects in the 
fruit fly Drosophila), pathway is one important signal pathway involved in embryonic 
development of the intestine as well as in cancer development of the colorectum104, 
230, 231. 
The role of β-catenin in colorectal carcinogenesis was first suggested by the 
association with the adenomatous polyposis coli (APC) protein, and by evidence of 
dysregulation of beta-catenin protein expression at all stages of the adenoma-
carcinoma sequence232, 233. However, several studies have shown that yet more 
components of colorectal carcinogenesis are linked to β-catenin pathways – thus 
making this protein a “linchpin” in CRC234. The oncogenic properties of Wnt/β-
catenin signaling stem from alteration in phosphorylation-dependent protein 
degradation and subcellular localization of beta-catenin from cell membrane to the 
nucleus, where it binds to T-cell factor (Tcf) to form a bipartite transcription factor. 
The β-catenin/Tcf complex facilitates transcription of target genes that encode 
effectors for activation of cell proliferation and invasion and inhibition of apoptosis, 
leading to colorectal cancer development 235. 
Pro-oncogenic factors that release β-catenin from the adherens complex and/or 
encourage translocation to the nucleus include RAS, EGF, c-erbB-2 and others, 
whereas anti-oncogenic factors (that also inhibit nuclear β-catenin signalling) include 
transforming growth factor (TGF)-β, retinoic acid, and vitamin D. Association of 
nuclear β-catenin with the Tcf/lymphoid enhancer factor (LEF) family of 
transcription factors promotes the expression of several compounds that have 
important roles in the development and progression of CRC. This include (but are not 
exclusive of) such genes and proteins as c-myc, cyclin D1, cyclooxygenase (COX)-2, 
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matrix metalloproteinases (MMPs), and several others 114, 236, 237. Genetic aberrations 
of several components of the β-catenin pathways, such as Frizzled (Frz), AXIN, and 
TCF-4, may potentially contribute to colorectal carcinogenesis. In addition, in the 
tumour invasion front, stabilized and activated β-catenin interacts with other 
molecular pathways to facilitate tumor progression. 
KRAS-BRAF-MAPK-pathway: K-ras is an oncogene which, when mutated, 
causes constitutively cell signal stimulus for cell-cycle entry and cell division. Recent 
evidence suggest that APC, K-ras, and p53 have different pathways and roles in CRC 
development 125, 126, 238. While the combination of APC/β-catenin and K-ras 
alterations are found in most CRCs232, they do not necessarily show a coexistence in 
all tumours. However, K-ras mutation, when it occurs (in about 35% of adenomas), 
seems to be an early event in adenoma-carcinoma development239, may have 
additional down-stream mutations in the pathways (i.e B-raf)240, is negatively 
associated with microsatellite instability190, and confer a poor prognosis in patients 
with CRC241.  
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3.4.2 Apoptosis 
Apoptosis is described by its morphological characteristics, including cell shrinkage, 
membrane blebbing, chromatin condensation and nuclear fragmentation. The 
realization that apoptosis is a gene-directed program (“programmed cell death”) has 
had profound implications for the understanding of developmental biology and tissue 
homeostasis, for it implies that cell numbers can be regulated by factors that influence 
cell survival as well as those that control proliferation and differentiation242. 
Moreover, the genetic basis for apoptosis implies that cell death, like any other 
metabolic or developmental program, can be disrupted by mutation. In fact, defects in 
apoptotic pathways are now thought to contribute to a number of human diseases, 
ranging from neurodegenerative disorders to malignancy, and the avoidance of the 
“cell death programme” is regarded one of the cancer hallmarks and an important 
feature in CRC 243, 244. In fact, inability to escape apoptosis could possibly explain the 
clinical notion of “regression” in many colorectal polyps245, 246 – and, inversely, an 
ability to grow and progress if the apoptotic mechanisms are avoided.   
 To important molecules in cancer development futher illustrated the importance 
of apoptosis control in cancer devlopment. One was the cloning and characterization 
of the bcl-2 oncogene, another was the p53 tumour suppressor gene.  
 bcl-2 was first identified in a human leukemia line and later in follicular 
lymphomas. Bcl-2 promotes cell survival by blocking apoptosis. To date, at least 15-
20 Bcl-2 family member proteins have been identified in mammalian cells, including 
proteins that promote apoptosis and those that prevent apoptosis. In addition to Bcl-2, 
Bcl-xL is a potent death suppressor that is upregulated in some tumour types. 
Conversely, Bax is a death promoter that is inactivated in certain types of colon 
cancer and in hematopoietic malignancies.  
 p53 was the first tumour suppressor gene linked to apoptosis. p53 mutations 
occur in the majority of human tumours and are often associated with advanced 
tumour stage and poor patient prognosis. By the early 1990s, p53 was established as a 
checkpoint protein involved in cell-cycle arrest and maintaining genomic integrity 
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following DNA damage. In addition, other stimuli can activate p53 to promote 
apoptosis, including hypoxia and mitogenic oncogenes. Moreover, several upstream 
and downstream components of the p53 pathway (such as Mdm-2, ARF and Bax) are 
mutated in human tumours.  
 Clearly, it is now known that mutations in many cancer-related genes in addition 
to bcl-2 and p53 can disrupt apoptosis during colorectal carcinogenesis 242-244. Several 
signal transduction pathways promote cell survival in response to growth and/or 
survival factors, and these pathways may be crucial in controlling cell numbers.  
 Molecules that regulate apoptosis can have other activities (and many of them 
do). For example, p53 can promote apoptosis, cell-cycle arrest and senescence such 
that loss of p53 function increases viability, chromosomal instability and cellular 
lifespan. In colon cancer, bax and p53 mutations appear mutually exclusive, 
consistent with a pathway relationship. In contrast, p21 which is essential for p53-
mediated arrest, is rarely mutated in human tumours. Some tumour-derived p53 
mutants remain capable of promoting cell-cycle arrest while losing their apoptotic 
potential. 
 A variety of signals appear important to trigger apoptosis during 
cancerogenesis242, 244. Extracellular triggers include growth/survival factor depletion, 
hypoxia, radiation and loss of cell-matrix interactions. Internal imbalances can also 
trigger apoptosis, including DNA damage (produced by cell-cycle checkpoint defects 
or exogenous toxins), telomere malfunction and inappropriate proliferative signals 
produced by oncogenic mutations. In some instances the apoptotic `trigger' actually 
alleviates an anti-apoptotic signal. For example, Insulin-like growth factor (IGF)-1 
promotes cell survival through the PI3K-pathway, and depletion of IGF-1 or other 
survival factors can trigger “death by default”. In contrast, other stimuli involve true 
pro-apoptotic factors; as an example, many forms of cellular stress can activate p53, 
which promotes apoptosis through pro-apoptotic molecules, like Bax.  
 The identification of apoptotic “triggers” provides insight into the forces of 
tumour evolution, both in initiating neoplasia development and in tumour 
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progression242, 244. Other apoptotic triggers are important in tumour progression. As 
developing tumours outgrow their blood supply, they encounter hypoxia (low 
oxygen), which can activate p53 to promote apoptosis. Cells acquiring apoptosis 
defects (such as p53 mutations) can survive hypoxic stress, leading to a clonal 
expansion within the tumour. Similarly, as developing tumour cells undergo repeated 
divisions, telomeres are shortened until some malfunction triggers either senescence 
or apoptosis. Like hypoxia, p53 is required for apoptosis induced by telomere 
malfunction; thus p53 mutant cells survive this response and are genomically 
unstable. Indeed, suppression of the apoptotic response to telomere malfunction may 
explain why combined loss of telomerase and p53 stimulates tumour development. 
This may explain why p53 mutations are usually late events in tumour development, 
as a cell acquiring a p53 mutation might not have a selective advantage until the 
developing tumour encounters hypoxic conditions or achieves sufficient telomere 
erosion.  
 Clearly, the molecular network in the regulation of apoptosis and proliferation 
is complex. However, a few important molecules deserve attention in the current 
setting. 
One is Survivin – a 16.5 kDa protein mapped to cromosome 17q25 – which 
was detected only a decade ago 247. Functionally, survivin is known to inhibit 
apoptosis, take part in cell division and mitogenic events such as control of 
microtubuli connection, and enhance angiogenesis 136, 248. The expression of survivin 
shows distinct differences between normal and malignant tissue and, plays a causal 
role in CRC progression 249, 250. Recently, a possible interrelationship between 
survivin expression and telomerase activity has been reported 249, as confirmed in this 
study. Endo et al 249 observed correlation between survivin and human telomerase 
reverse transcriptase (hTERT) expression in colon cancer tissues, and 
overexpression of survivin enhanced telomerase activity by up-regulation of hTERT 
expression in human CRC cells. This is in line with our findings of the co-expression 
of these two markers 251. 
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Human telomeres are composed of long repeating sequences of “TTAGGG”, 
associated with a variety of telomere-binding proteins. The function of hTERT as an 
end-protector of chromosomes prevents the chromosome from end-to-end fusion, 
recombination and degradation. hTERT acts as a reverse transcriptase in the 
elongation of telomeres, which prevent the loss of telomeres during replication.  
In most tumour cells, telomeres are extremely short and stable. Telomere length is an 
important indicator of the telomerase activity in tumour cells and it may be used in 
the prognosis of malignancy, including colorectal neoplasia 252. hTERT activation or 
up-regulation causes an indefinite cell proliferation. This cellular immortalization is a 
potentially rate-limiting step in carcinogenesis that is important for the continuing 
evolution of most advanced cancers. In CRC development, hTERT activation occurs 
during the progression from low-grade to high-grade IEN in adenomas and increases 
steadily with the progression of the degree of dysplasia and invasion during colorectal 
carcinogenesis 252-255. Telomere instability causes increased expression of p16INK4a 256.  
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4. BIOMARKER DISCOVERY 
 
4.1 DIAGNOSTIC ACCURACY 
Diagnostic accuracy is the ability of a laboratory test to correctly classify subjects 
into clinically relevant groups (i.e. cancer vs. no cancer). Diagnostic accuracy refers 
to the quality of the information provided by the classification device (i.e. cut-off 
level for a continuous variable) and should be distinguished from the usefulness, or 
actual practical value, of the information 257. 
Diagnostic tests are usually measured and interpreted in their applicability by a 
number of features, including258: 
 Sensitivity, or the True Positive rate, which tells how good the test is at 
picking up people with the condition investigated. A high sensitivity is typically 
preferred in a screening test to rule out people without the disease. 
 Specificity, or the True Negative rate, which tells how good the test is at 
correctly defining people without the disease. A high specificity is required for 
diagnostic tests in order to have a low false positive rate. 
 Positive predictive value (PPV, or the post-test probability of a positive 
test), which is a measure of the probability of having the condition if a person tests 
positive. 
Negative predictive value (NPV, or the post-test probability of a 
negative test); will address the situation “if a patient/person tests negative on a test, 
what is the probability of not having the condition/disease”. 
Accuracy, gives the proportion of all tests that have given the correct result 
(true positives and true negatives) as proportion of all the results. 
 
 49 
Sensitivity and specificity are features of the test itself, and “looks backward” 
in that they show the probability that a person with a disease will have a positive test, 
rather than “looking forward” and showing the probability that the person who tests 
positive actually has the disease 259. 
Likelihood ratios (LR) is an estimate of the relative predictive value of a test 
(true positives/false positives), is useful in clinical practice as it indicates how likely a 
positive result will be found in a person with the disease compared to a person 
without the disease. LR of a test indicates the increase from pre-test probability (e.g. 
prevalence of the disease) to post-test probability. Interpretation of LRs can be used 
by nomograms. As a rule of thumb, LR over 10 is generally regarded as large and a 
conclusive change in pre- to post-test probability of having the disease. LR of 5-10 
are considered moderate, and LR<2 are rarely considered important 259. For tests with 
a continuous range of test-results (e.g. from 1-100), rather than a dichotomous test-
result (yes/no; red/green; present/absent), the sensitivity and specificity (and the LR) 
heavily relies on the chosen cut-off value for dichotomization into f. ex. healthy vs 
diseased. 
As an example, expression (positive stain) of any protein biomarker in 
cancerous tissues produces a continuous spectrum of test results (i.e. from 0-100%). 
Thus, the diagnostic properties of such biomarkers (as expressed by sensitivity, 
specificity, predictive values, or likelihood ratios) depend on the chosen cut-off value 
to differentiate between normal and disease states 260.  
 Receiver-operating characteristics curve (ROC) analysis provides a 
statistical method to assess the diagnostic accuracy of a test with continuous spectrum 
of results 261. The ROC curve is a graphical display of the true-positive rate 
(sensitivity, y-axis) and the false-positive rate (1-minus-specificity; x-axis). Each 
classification rule, or cut-off level, generates a point on the graph. The traditional 
ROC curve arises when a continuous value is measured in each subject and the 
classification is positive if the value is above a threshold. As the threshold varies, a 
new classification rule is created, and the resulting plot is a single curve. The optimal 
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ROC curve is the line connecting the points highest and farthest to the left-upper 
corner. The rationale for the optimal ROC curve is that it captures the trade-off 
between sensitivity and specificity over a continuous range. The area under the curve 
(AUC) is a measure of overall diagnostic accuracy of the test, and the cut-off value 
providing the highest sensitivity and specificity is calculated. Importantly, the results 
are independent of the prevalence of the disease. Furthermore, ROC plots occupy a 
central position in the process of assessing and using diagnostic tools 37, 257, 261. 
 
 
4.2 SURROGATE ENDPOINTS BIOMARKER (SEPB) 
 
Intraepthelial neoplasia (IEN): As a near obligate precursor to cancer, the 
intraepithelial neoplasia (IEN) is an appropriate target for intervention. Occurring in 
most gastrointestinal epithelial tissues as moderate to severe dysplasia, IEN shares 
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phenotypic and genotypic similarities with invasive disease and is on the causal 
pathway leading from normal tissue to cancer. In addition, IEN serves as a significant 
risk marker for cancer. Subjects with IEN, particularly those with severe IEN, are at 
significantly higher risk than unaffected individuals for developing invasive cancer in 
the same tissues. This risk in fact exceeds other measurable factors (e.g., age, race, 
and family history), with the exception of germ-line mutations that occur in genetic 
syndromes. IEN is also a disease in its own right, in that treatment provides clinical 
benefit. In standard clinical practice, surgical interventions are used to reduce the 
burden of IEN. This same goal of reducing IEN burden is thus also appropriate for 
medical (noninvasive) intervention, not only to reduce invasive cancer risk, but also 
to reduce surgical morbidity.  
 The colorectal adenoma is an IEN prototype and a good example for 
using IEN as surrogate end-points (SEPs). Knowledge of the biology of tumour 
progression therefore allows us to identify specific tests that are useful for early 
detection or screening 95. Molecular probes, for instance, could detect altered DNA 
shed into the faeces 89. Correlation of the molecular alterations with demographic 
data, risk factors, environmental exposure, family history, and dietary history may 
provide important information on the aetiology of CRC. Molecular genetic alterations 
could also contribute toward the assessment of risk. Risk assessment is the search for 
risk factors that provide the earliest evidence for the risk of cancer in persons not 
diagnosed with the disease. Biomarkers that are predictive of risk can potentially 
trigger more aggressive interventions and surveillance. Individuals who test positive 
for any risk marker become candidates for an intervention or for surveillance. The 
earliest risk factors are probably the inherited genetic defects, which is well 
demonstrated in the case of CRC (for example patients with HNPCC or FAP). 
 Markers of risk and markers of early detection share the same outcome, 
namely, the incidence of disease. However, markers of risk and markers for early 
detection differ in the degree of certainty they convey regarding the existence of 
cancer. A risk factor confers significantly less than 100% certainty of cancer within a 
specified time interval, whereas early detection markers confer close to 100% 
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certainty of cancer. Risk markers indicate that cancer is more likely to occur within a 
specified time in persons with the marker than in the general population. Early 
detection markers indicate the existence of cancer, or that cancer will occur with 
nearly a 100% certainty within a specified time interval.  
 From a screening perspective, all surrogate outcomes in individuals not 
diagnosed with cancer are risk factors. Colonic polyps, for instance, are a surrogate 
end point for screening and a risk factor for colon cancer 95, 262. The elements that are 
necessary in order to use risk factors as surrogate outcomes in screening, early 
detection, or prevention interventions are somewhat different. However, for a risk 
factor to be a useful SEPB, it must be strongly connected to the definitive outcome, 
and the probability and direction of the relationship must be known. Several criteria 
must be met before biomarkers can serve as risk factors or as markers for early 
detection95, 263, 264, for which some steps are crucial:  
• the biomarker must be differentially expressed in normal, premalignant or 
high-risk, and tumour tissue;  
• the marker and its assay must provide acceptable predictive accuracy for 
risk or for the presence of cancer; and  
• the variance of the detection tests and the intra- and interlaboratory 
variance must be known.  
Risk markers are usually used as surrogate outcomes to detect the effect of a 
prevention intervention more rapidly than waiting for the definitive outcome. These 
criteria can be tested and evaluated in animal models and in human tissue specimens. 
Today, there are very few biomarkers for risk of colon cancer, except for the colonic 
adenoma per se94, 95. 
 
4.3 ENDPOINT: SYNCHRONOUS vs METACHRONOUS CANCER  
Metachronous neoplasia development after having an adenoma has been investigated 
in a number of ways, with a large number of parameters and techniques, but 
unfortunately from very heterogeneous populations, and with inconsistent use of 
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endpoints (any adenoma, advanced adenoma, or cancer) and definition of the 
“metachronous interval” 80, 96, 118, 265-268. “Metachronous cancer” development is (most 
frequently) defined as detection of a second cancer occurring beyond a 6-12 months 
interval after a primary, index cancer diagnosis/surgery41, 214, 269-271. For cancers 
developed after adenoma detection and/or polypectomy a “long-term” risk or an 
undefined metachronous cancer risk has been stated, as opposed to “synchronous” 
cancers detected in the same-session endoscopic procedure. In the adenoma study, we 
defined metachronous cancers as cancer developing after at least 24 months interval 
from the index adenoma 80, 118, to avoid a high incidence of missed synchronous 
cancers. 
 
4.4 GENOMICS & PROTEOMICS 
4.4.1 The potential 
Year 2003 marked the 50th anniversary of the 1953 landmark description of the DNA 
double helix 272. The same year the Human Genome Project completed the 
successfully sequencing of the human genome 273, 274. These are major achievements 
in biology and medicine in general, not the least to the understanding of 
carcinogenesis. New molecular insights and technologies have given clues to the 
initiation, early detection and possible prevention of neoplasia, prognostic and 
predictive markers in oncology, and targets for early detection and therapy. Modern 
molecular medicine is thought to overtake the current use of pathologist dysplasia 
classification and tumour-staging systems in the future68, 275. 
The search for cancer-causing alterations within the currently known genes of 
the whole genome (Genomics – the study of the human genome) is complexed by the 
different ways the genes may be transcribed (Transcriptomics) into a variety of 
functionally different proteins (Proteomics – the analysis of the protein complement 
of the genome), which themselves over time can undergo essential functional 
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changes. Each has the potential for discovery of new diagnostic biomarkers, therapy 
targets, and predictive and prognostic features276. 
An analogue to the understanding of the genetic code is the comparison with 
the alphabet. As such, we have discovered the letters (the sequence) and have thus far 
found a few sentences (genes that we know of), but we have only merely begun 
reading the chapter contents (how genes may be transcribed), while the books (the 
proteins and the metabolites) will keep mankind reading for many centuries to come. 
Obviously, the human/mammalian library contains many books. In more scientific 
terms, the outline of the genome has enabled the study of gene products that are the 
focal point of proteomic studies, the effectors of the DNA277. Thus, considering the 
complexities of human nature and disease processes, we have just become aware of 
the alphabet-code for a vast library of knowledge.  
 
4.4.2 The pitfalls 
Genomic medicine is poised to offer a broad array of new genome-scale screening 
tests. However, these tests may lead to a phenomenon in which multiple abnormal 
genomic findings are discovered, recently coined “incidentalomics”278, analogous to 
the "incidentalomas" that are often discovered in radiological studies. If practitioners 
pursue these unexpected genomic findings without thought, there may be disastrous 
consequences. One recent example of this in Norwegian medicine is the fecal gene-
testing initiated for colorectal (pre-)neoplasia detection prior to any evidence that this 
really improve detection and work-up in symptomatic patients 279. 
First, physicians, as well as researchers, will be overwhelmed by the 
complexity of pursuing unexpected genomic and proteomic measurements. This is 
underlined by the notion that according to our existing knowledge, only 1.1% of the 
genome consists of exons coding for proteins, 24% is intronic sequences and the 
remaining 75% consists of intergenic DNA currently without a known function 
(although knowledge is evolving rapidly) in RNA-transcription or protein translation.   
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Second, patients will be subjected to unnecessary follow-up tests, causing 
additional morbidity, and potentially impaired quality of life. While molecular 
markers have the potential for non-invasive, large-scale screening, such as panels 
used for faecal detection of occult genes for colorectal cancer280, 281, the 
implementation of such tools require crucial attention to every step in the 
implementation process, including assessment of diagnostic accuracy, reliability, 
validity, cost-effectiveness, and risk-benefit analysis. Commercial benefits alone 
should not justify nationwide implementation279. 
Third, the cost of genomic medicine will increase substantially with little 
benefit to patients or physicians (but with great financial benefits to the genomic 
testing industry279), thus throwing the overall societal benefit of genome-based 
medicine into question. Several authors have discussed the basis for these concerns 
and suggested similar approaches through several steps that can be taken to help 
avoid the risks to the practice of genomic, personalized medicine 148, 263, 278, 282-284. 
That molecular markers can accurately diagnose cancer have been claimed and 
disputed; some prominent results have not been reproduced and bias has been 
proposed to explain the original observations282, 285. As new Omics-fields are explored 
to assess molecular markers for cancer, bias will increasingly be recognized as the 
most important 'threat to validity' that must be addressed in the design, conduct and 
interpretation of such research. 
Although molecular markers will undoubtedly provide advances in diagnosis 
and prognosis, the degree of success claimed at present is extraordinary. In an 
example, the carcino-embryonic antigen (CEA) was several decades ago purported to 
be nearly “…100% sensitive and specific…” for colorectal cancer screening in initial 
research, whereas subsequent research had very different results. History might not 
necessarily repeat itself, but it indicates caution before making claims of success. The 
non-reproducibility of the CEA results was due, in large part, to the fact that 
individuals who were initially studied had extensive cancer, whereas individuals who 
were later studied had less extensive asymptomatic cancer in which CEA might not 
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have been increased282, 286. The fact that test results vary with the ‘spectrum’ of 
disease might seem obvious now37, 41, but there was little understanding in that era of 
the concept of spectrum of testresults and of the biases that affect research about 
diagnostic tests282, 286. Development of the methods and rules of evidence by which 
diagnostic tests are judged today occurred in part because of the CEA experience and 
should guide future study design264, 282, 286. 
 
4.4.3 Some techniques 
The techniques used in modern molecular biological medicine continuous to evolve 
and improve, and includes a plethora of possible approaches to explore, measure and 
investigate the human genome and its by-products (proteins). Reviews covering 
several techniques have been given in more recent publications147, 148, and but a few 
examples are mentioned here: 
 Immunohistochemistry (IHC): refers to the process of localizing proteins in 
cells of a tissue section exploiting the principle of antibodies binding specifically to 
antigens in biological tissues. It takes its name from the roots "immuno," in reference 
to antibodies used in the procedure, and "histo," meaning tissue. IHC staining is 
widely used in the diagnosis and treatment of cancer. Specific molecular markers are 
characteristic of particular cancer types. IHC is also widely used in basic research to 
understand the distribution and localization of biomarkers in different parts of a 
tissue. Visualising an antibody-antigen interaction can be accomplished in a number 
of ways, either by the direct or indirect method. In the most common instance, an 
antibody is conjugated to an enzyme, such as peroxidase, that can catalyse a colour-
producing reaction. 
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Figure: The basic principles of immunohistochemistry. 
 
 Tissue microarrays (TMA): is an array-based, high-throughput technique that 
facilitates gene expression and copy number surveys of very large numbers of 
tumours. Up to 1000 cylindrical tissue biopsies (though typically lower, e.g. 40-60 
per block) from individual tumours can be distributed in a single tumour tissue 
microarray. Sections of the microarray provide targets for parallel in situ detection of 
DNA, RNA and protein (IHC) targets in each specimen on the array, and consecutive 
sections allow the rapid analysis of hundreds of molecular markers in the same set of 
specimens. TMA technology is of substantial value in rapidly translating genomic 
and proteomics information to clinical applications287-289. Due to variety in core 
diameter (i.e. from 0.6 micrometers-2.0 micrometers), number of cores (1-3 per 
specimen), tumour heterogeneity (invasive front, tumour centre etc) there is a risk for 
sampling error and low reproducibility with careless use of this technique. 
 
Figure: Construction of tissue microarray (TMA) for high-throughput analysis of antigens. 
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 Polymerase chain-reaction (PCR): is a biochemistry and molecular 
biology technique for exponentially amplifying DNA via enzymatic replication. As 
PCR is an in vitro technique, it can be performed without restrictions on the form of 
DNA, and it can be extensively modified to perform a wide array of genetic 
manipulations. In 1983, the PCR technique was invented by Kary B. Mullis. He 
received the Nobel Prize in Chemistry in 1993 for his invention. PCR is now a 
common technique used in medical and biological research labs for a variety of 
tasks (ranging from cancer/disease research and diagnosis, to genetic 
“fingerprinting”, paternity issues and forensic sciences). One such applicable area 
for the use of PCR is the testing of microsatellite instability in cancers from patients 
with (clinically suspected) hereditary non-polyposis colorectal cancer (HNPCC). 
PCR is used to amplify specific regions of a DNA strand. This can be a single 
gene, just a part of a gene, or a non-coding sequence. PCR, as currently practiced, 
requires several basic components, including chemical components and buffers. 
The most important components are: 
1. DNA (“template”) that contains the region of the DNA fragment to be amplified 
2. One or more primers (i.e. MSI markers or the like), which are complementary to 
the DNA regions at the 5' and 3' ends of the DNA region that is to be amplified. 
3. a DNA polymerase (e.g. Taq polymerase or another DNA polymerase with a 
temperature optimum at around 70°C), used to synthesize a DNA copy of the 
region to be amplified. 
4. Deoxynucleotide triphosphates, (dNTPs) from which the DNA polymerase builds 
the new DNA. 
 
The PCR is carried out in small reaction tubes that are inserted into a thermal cycler 
that heats and cools the reaction tubes to the precise temperature required for each 
step of the reaction. In practice, PCR can fail for various reasons, in part due to its 
sensitivity to contamination causing amplification of spurious DNA products. 
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Because of this, a number of techniques and procedures have been developed for 
optimizing PCR conditions. Contamination with extraneous DNA is addressed with 
lab protocols and procedures that separate pre-PCR reactions from potential DNA 
contaminants. 
Other proteomic technologies: The definition of proteomics has greatly changed over 
time. Originally it was coined to describe the large-scale, high-throughput separation 
and subsequent identification of proteins resolved by 2-dimensional polyacrimide gel 
electrophoresis (2DE). Currently “proteomics” denotes to nearly any type of 
technology focusing upon proteins analysis, ranging from a single protein to thousand 
in one experiment. Proteomics thus has replaced the phrase protein science.  
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II. AIMS OF STUDIES 
 
The use of colorectal adenomas and intraepithelial neoplasia (IEN) as a surrogate 
enpoint biomarker for colorectal cancer is extensive. It is the current target for 
diagnosis, therapy and prevention of colorectal cancer and its precursors. However, 
the diagnostic accuracy and predictive value of the IEN in colorectal adenoma for 
long-term, metachronous cancer development is not optimal. A major focus has been 
on the detection of synchronous (”same time”) cancer in patients with colorectal 
adenomas rather than the long-term risk of (metachronous) colorectal cancer. The 
majority of adenomas never progress to cancer, thus, defining patients with adenomas 
at high-risk for cancer development would be beneficial in surveillance after 
polypectomy. The objectives of the studies on colorectal adenomas were: 
• to find new and better morphologic/morphometric predictors of metachronous 
CRC development by investigating a large set of quantitative morphometric cell 
features within adenomas, by using digitalized objective image analysis (paper II: 
Søreide K, et al. Am J Surg Pathol 2006;30(9):1120-9). 
• to further investigate selected morphometric cell features together with a large 
number of cell-cycle and apoptosis-related proteins by immunohistochemistry. 
Again the objective was to find new and better predictors of metachronous CRC 
development (paper IV: Søreide K, et al. Cell Oncol 2007;29(4):301-13). 
• to find optimal cut-offs for biological markers investigated in paper II and IV and 
validate these in a larger set of patients. The cut-offs were evaluated by receiver 
operating characteristics curve (ROC) analysis, and useful predictors identified by 
multivariate analysis. (paper V: Søreide K, et al submitted 2007). 
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After surgery for colorectal cancer, national Norwegian guidelines mandates 
systematic follow-up to detect curable, asymptomatic recurrences or curable 
metastatic disease. This surveillance is performed within a comprehensive program, 
based on serial CEA measurements and clinical visits, in addition to radiologic 
investigations and endoscopy. Hitherto, the effectiveness and outcome of this 
programme have not been evaluated in clinical practise. The objectives of the studies 
were: 
• to evaluate the effectiveness, costs and compliance to the systematic follow-up 
programme recommended by the Norwegian Gastro-Intestinal Cancer Group 
(NGICG) in a consecutive cohort of patients undergoing surgery for CRC with 
curative intent (paper I: Kørner H, Søreide K et al. J Gastrointest Surg 
2005;9(3):320-8). 
• to evaluate the diagnostic accuracy of serial measurements of CEA to detect 
asymptomatic, recurrent disease amenable for secondary curative surgery. 
ROC analysis was used to evaluate various cut-off levels, as well as the slope 
of increase in CEA from post-operative baseline to the CEA value associated 
with diagnosis of recurrence. (paper III: Kørner H, Søreide K et al. Ann Surg 
Oncol 2007;14(2):417-23). 
• to evaluate the role of microsatellite instability and DNA ploidy in relation to 
clinicopathological features, risk of any recurrence (both locoregional and 
distant metastasis) and disease-specific survival in a patient cohort undergoing 
systematic follow-up after curative surgery for CRC (paper VI: Søreide et al. 
submitted 2007).  
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III. RESULTS OF STUDIES 
 
Studies on colorectal adenomas 
In paper II (Søreide K, et al. Am J Surg Pathol 2006;30(9):1120-9) we 
investigated a large set of quantitative morphometric cell features within adenomas, 
by using digitalized objective image analysis. We evaluated the prognostic value of 
classical clinicopathologic features and a monotonous population of elongated cells 
(MPECs) in colorectal adenomas from 171 consecutively selected patients from a 
defined population and with long-term follow-up. Quantitative image analysis, and 
univariate and multivariate regression analysis were applied. Ten of 171 patients with 
adenomas (5.8%) developed metachronous CRC (defined as >24 mo interval and >5 
cm from the index adenoma to the cancer). Median follow-up of adenomas with 
metachronous CRC was 68.4 and without cancer 149.7 months (range: 25 to 192 and 
25 to 256, respectively). The most prognostic classical features were the localization 
of the marker adenoma as proximal (i.e., in the coecum through transverse colon) 
versus distal from the transverse colon [P=0.0003, hazard ratio (HR)=8] and the 
number of polyps found during colonoscopy (<or=2 vs >2, P=0.002, HR=6). 
Quantitative features of the MPECs included the longest nuclear axis and variance of 
the number of nuclei with 2 neighbors (higher and lower in cancer cases, 
respectively). Of the 171 adenomas, 50 (29%) had MPECs, of which 9 (18%) patients 
developed metachronous CRC at follow-up, contrasting 1/121 (0.8%) without 
MPECs (P=0.0003, HR=23). MPECs occurred in both low-grade and high-grade 
dysplasia, and in tubular and (tubulo) villous adenomas. MPECs had the strongest 
prognostic value for metachronous CRC development. Adenomas proximally located 
had additional value but only if they were MPEC positive (which only occurred in 5 
adenomas, 3 of which (60%) developed cancer). Having more than 2 polyps also had 
additional prognostic value but only in MPEC-negative adenomas [10 cases; 1 (10%) 
developed cancer]. Dysplasia grade and histologic growth pattern had no additional 
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value. Thus, colorectal adenomas with subsequent metachronous cancer development 
can be identified more accurately with MPECs than with classical prognostic factors. 
 In paper IV (Søreide K, et al. Cell Oncol 2007;29(4):301-13) we investigated 
morphometric cell features together with a large number of cell-cycle and apoptosis-
related proteins by immunohistochemistry on tissue microarrays (TMA). We assessed 
the differential expression of cell-cycle and apoptosis-regulating proteins and a 
monotonous population of elongated cells (MPECs) in colorectal adenomas. 
Immunohistochemistry was performed on tissue microarrays in consecutive patients 
having colorectal adenomas and with long-term follow-up. Influence of classic 
features (e.g., intraepithelial neoplasia grade, histological type, size) was examined. 
Of 171 patients with colorectal adenoma 86% (n=147) were eligible for study; 10 
(7%) developed metachronous CRC. Median time to cancer was 69 months (range, 
25–256). Median follow-up was equal for the non-cancer and cancer groups. Elevated 
expression of cell-cycle regulators p16INK4A, p21CIP1, and cytoplasmic/nuclear β-
catenin correlated with increased CRC risk (all P < 0.0001), as did elevated 
expression of the anti-apoptosis protein survivin (P< 0.0001) and human telomerase 
reverse transcriptase (hTERT; P < 0.001). Survivin, hTERT, and nuclear β-catenin 
were the most predictive molecular markers (hazard ratios [HRs]: 6.3, 9.4, and 5.8, 
respectively). In a combined multivariate model, MPECs had the best overall 
prognostic ability (HR 28.2, 95% CI: 3.6–223.0), together with survivin, and hTERT. 
Within adenomas containing MPECs, several molecular markers further defined 
high-risk patients. MPECs, survivin and hTERT may, when validated, provide 
information superior to conventional histology, with relevance for the clinical 
management of patients with colorectal adenoma. 
 In paper V (Søreide K, et al submitted 2007) the investigated features in paper 
II and IV were validated in a second and larger set of patients (n=227=), and 
evaluated by ROC analysis for optimal cut-offs and useful predictors identified by 
multivariate analysis. We sought to validate biomarkers predictive of metachronous 
colorectal cancer (mCRC) in patients with sporadic colorectal adenomas from 374 
consecutive patients within a defined population. Risk-evaluation was performed for 
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patient and adenoma (i.e. grade, size, multiplicity) risk factors, morphometric nuclear 
axis, and immunohistochemistry (survivin, hTERT, β-catenin, p16INK4a, p21CIP1, 
cyclin D1). Diagnostic accuracy was assessed by receiver-operating characteristics 
(ROC) curve analysis, and uni- and multivariate analysis performed by Kaplan-Meier 
survival plot and Cox proportional hazards methods. Of the 374 patients, 26 (7%) 
developed mCRC with a median of 5.6 yrs (range 2-19) from index adenoma. Age 
≥60 yrs, proximal location, multiplicity (≥3 adenomas), and high-grade neoplasia 
were independent risk factors, with high-grade IEN and proximal location the 
strongest on multivariate analysis (hazard ratio=HR of 4.1 and 5.2, respectively; both 
p<0.05). The molecular markers had significant independent value, while hTERT 
(HR 11.3, 95% CI 3.9-33.1; p<0.001) and survivin (HR 7.0, 95% CI 2.4-20.5; 
p<0.001) were the strongest, only retaining proximal location (4/16=25% with 
mCRC) in the combined multivariate model. The value of hTERT and survivin were 
retained in the validation set. The combination of survivin and hTERT yielded high 
mCRC risk when both were positive (15/51=29%; OR 14.3, 5.6-36.5), modest for one 
positive (survivin 4/90=4.4%; hTERT 4/60=6.7%) and no risk if both were negative 
(0/144=0%). The multivariate risk-model showed that hTERT and survivin are the 
best risk-predictors for long-term, metachronous CRC development in patients with 
sporadic colorectal adenomas. 
 
Studies on surveillance after surgery for colorectal cancer 
 In paper I (Kørner H, Søreide K et al. J Gastrointest Surg 2005;9(3):320-8) 
the effectiveness, costs and compliance to this programme was evaluated in 
consecutively accrued patients undergoing surgery for CRC with curative intent. In 
194 (62%) of the patients, follow-up was conducted according to the Norwegian 
guidelines. Twenty-one patients (11%) were operated on for curable recurrence, and 
18 patients (9%) were disease free after curative surgery for recurrence at evaluation. 
Four metachronous tumors (2%) were found. CEA interval measurement had to be 
made most frequently (534 tests needed) to detect one asymptomatic curable 
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recurrence. Cancer-specific survival did not differ among those patients with 
compared without systematic surveillance after surgery. Overall compliance with the 
surveillance program was 66%, being lowest for colonoscopy (55%) and highest for 
ultrasonography of the liver (85%). The total program cost was 228,117 euro (US 
280,994 dollars), translating into 20,530 euro (US 25,289 dollars) for one surviving 
patient after surgery for recurrence. The total diagnostic yield with regard to disease-
free survival after surgery for recurrence was 9%. Compliance was moderate. The 
results call for a discussion on the usefulness and cost-benefit of mandating this 
programme at a national level. 
 In paper III (Kørner H, Søreide K et al. Ann Surg Oncol 2007;14(2):417-23) 
the diagnostic accuracy of serial measurements of CEA was performed, using ROC 
analysis and evaluating various cut-offs and the slope of increase in CEA. One 
hundred ninety-four consecutive patients surgically treated with curative intent for 
CRC between July 1996 and June 1999 had systematic follow-up for five years. 
Follow-up included radiologic imaging, coloscopy and serial CEA measurements. 
Complete data including CEA measurements were available from 153 patients. ROC 
analysis of CEA was done with regard to detection of recurrent disease. Depending 
on the chosen cut-off value of CEA, the diagnostic accuracy (DA) varied widely 
within the normal range (CEA <or=10 U/ml). CEA >4 U/ml provided the highest 
sensitivity (0.78) and specificity (0.91), compared to a sensitivity and specificity at 
the upper normal range (CEA = 10 U/ml) of 0.51 and 0.99, respectively. Thirty-three 
patients (24%) developed recurrence. Among 11 (5%) asymptomatic patients 
diagnosed by elevated CEA levels, only two patients (1.5%) were amenable to 
secondary curative surgery. A threefold increase of CEA in an individual patient had 
the same DA as the best cut-off value (>4 U/ml). In conclusion, the diagnostic 
accuracy of CEA in follow-up after curative surgery for CRC is influenced by the 
chosen cut-off value. A threefold increase of CEA may indicate recurrent disease. In 
conclusion, we found that the value of serial measurement of CEA was limited. 
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 In paper VI (Søreide K et al. submitted 2007) we evaluated the effect of 
microsatellite instability and DNA ploidy in relation to survival and risk of recurrence 
or distant metastasis in patients undergoing systematic follow-up after surgery for 
CRC. We investigated the impact of MSI on recurrence patterns and survival in 186 
patients undergoing systematic surveillance after CRC surgery with curative intent. 
Systematic follow-up was performed according to Norwegian Gastro-Intestinal 
cancer Group (NGICG) guidelines. PCR-technique was used to analyze for MSI 
using quasi-monomorphic markers (BAT-26, BAT-25, NR-21, NR-24, and NR-27), 
and image cytometry for ploidy analysis. Tumour features were investigated with 
regard to risk for any recurrence (locoregional or distant metastasis), time to 
recurrence, recurrence-free survival (RFS) and disease-specific survival (DSS) with 
uni- and multivariate methods. Median age at diagnosis was 67 years; median follow-
up time 6.2 years. Patients with MSI (n=37; 20%) were significantly younger (median 
61 yrs; P=0.016). MSI tumours were significantly more often found in proximal 
colon, were larger, of more invasive nature (pT3-4), were diploid and low histologic 
grade, and had a more advanced stage (stages II or III) than their MSS counterparts. 
MSI was not associated with increased risk for any recurrence (odds ratio [OR]=1.2, 
95% confidence interval [c.i.] 0.6-2.4), but had a higher OR for developing 
locoregional recurrence (27% vs 11%, respectively; OR 2.9, 95% c.i. 1.2-7.0; 
P=0.016). Also, a non-significant trend towards shorter time to locoregional 
recurrence (P=0.060) was noted for MSI cancers. MSI-status did not influence on 
RFS and DSS, nor did any of the DNA histograms, including ploidy. TNM-stage with 
nodal status was the overall best predictor of DSS (hazard ratio [HR]=4.9, 95% c.i. 
2.6-9.0; P<0.001). In conclusion, TNM-stage, explained by nodal status (pN+) had 
the most prognostic feature for RFS and DSS in the selected patient cohort. MSI had 
no prognostic value on RFS or DSS in patients undergoing systematic surveillance 
after curative surgery for CRC. Risk for locoregional recurrence was significantly 
increased in MSI, with a trend towards shorter time to locoregional recurrence. This 
knowledge could be of clinical importance for the choice of surveillance modality 
(i.e. endoscopy vs radiologic imaging).  
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IV. FUTURE DIRECTIONS & CHALLENGES 
As depicted in the general introduction and summary of the papers in this thesis, 
colorectal neoplasia (both precursors and cancer) will continue to pose a great health 
burden in the years to come. The understanding of colorectal carcinogenesis is 
rapidly evolving, however, clinical translation of the basic science results are not 
easily overcome and may take years to implement. However, the first “targeted 
therapies” have evolved into clinical use based on molecular knowledge – new modes 
of detection and prevention are likely to follow in due course as well.  
In the overall management of colorectal pre-neoplasia it appears important to be 
able to identify patients (with adenomas) having high-risk features for better 
surveillance after polypectomy. Markers that can be both risk-markers and targets for 
(medical preventive) therapy would be optimal for detection and prevention. In 
addition, if nationwide screening is implemented, risk markers beyond the traditional 
adenoma may be required to better address the surveillance of patients over time. 
Furthermore, as the population grows older, still more will live to develop colorectal 
cancer – post-surgery surveillance with “one size fits all” will represent a 
considerable socio-economic health burden if not improved by risk-stratification and 
tailored follow-up 290.  
Thus, future exploration of riskmarkers in preneoplasia and colorectal cancer needs 
to address this based on the known and evolving genetic pathways in colorectal 
carcinogenesis 291. Together with the utilization of modern molecular techniques in 
genomic and proteomic sciences new markers of disease or risk will evolve.  
Lastly, succeeding in this task requires collaboration between disciplines – a hurdle 
sometimes more difficult to overcome than understanding the human genome itself. 
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VI. ERRATA 
 
Paper 1: J Gastrointest Surg 2005;9(3):320-8. 
In figure 3, the box titled “no evidence of disease” the correct number of patients 
should read 116 (not 186). 
 
Paper 2: Am J Surg Pathol 2006;30(9):1120-9. 
Table 2, the rows 5 and 6 (from the top) should read: 
No. of adenoma 
   ≤2 
   >2 
 
155 
16 
 
7 
3 
 
245 (237–254) 
201 (160–241) 
0.01 
Size 
  ≤ 2 cm 
  >2 cm 
 
101 
70 
 
4 
6 
 
247 (238–255) 
237 (222–252) 
0.29 
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